ABSTRACT
Objectives Macrophage activation syndrome (MAS) is a severe, life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). The objective of this study was to confirm the adequacy of an emapalumab dosing regimen in relation to interferon-γ (IFNγ) activity by assessing efficacy and safety. The efficacy outcome was MAS remission by week 8, based on clinical and laboratory criteria.
Methods We studied emapalumab, a human anti–IFNγ antibody, administered with background glucocorticoids, in a prospective open-label, single-group trial involving patients who had MAS secondary to sJIA or AOSD and had previously failed high-dose glucocorticoids. The study foresaw 4-week treatment that could be shortened or prolonged based on investigator’s assessment of response. Patients could enter a long-term (12 months) follow-up study.
Results Fourteen patients received emapalumab. All patients completed the trial, entered the long-term follow-up and were alive at the end of the follow-up. The investigated dosing regimen, based on an initial loading dose followed by maintenance doses, was appropriate, as shown by rapid neutralisation of IFNγ activity, demonstrated by prompt decrease in serum C-X-C motif chemokine ligand 9 (CXCL9) levels. By week 8, remission of MAS was achieved in 13 of the 14 patients at a median time of 25 days. Viral infections and positive viral tests were observed during the trial and during the long-term follow-up.
Conclusions Neutralisation of IFNγ with emapalumab was efficacious in inducing remission of MAS secondary to sJIA or AOSD in patients who had failed high-dose glucocorticoids.
What is already known on this topic?Macrophage activation syndrome (MAS) is a severe and potentially life-threatening complication of systemic juvenile idiopathic arthritis and adult-onset Still’s disease. There are no therapeutic options that have been prospectively investigated in MAS. Data in animal models and ex vivo data from humans with MAS led to the hypothesis that interferon-γ (IFNγ) has a pathogenic role in MAS.
What does this study add?This open-label multicentre trial using emapalumab, an anti–IFNγ antibody, in patients who have failed to respond to high-dose glucocorticoids, demonstrates that IFNγ has a pathogenic role in MAS and that its neutralisation leads to MAS remission.
How might this affect research, clinical practice or policy?The results of this study show that neutralisation of IFNγ with emapalumab is a therapeutic option for patients with severe MAS who have failed standard of care with high-dose glucocorticoids.
Competing Interest Statement
FDB: Consultant and research grants from AbbVie, Sobi, Pfizer, Roche, Sanofi, Novartis, Novimmune; AG: Consultant for Novartis, AB2 Bio, Novimmune, Sobi; PB: Consultant for Sobi, Novartis, Roche, UCB; CB: None declared. MP: None declared. GM: None declared; DE: Speaker bureau for Sobi; CP: Speaker bureau for Sobi; GS: Consultant for Novartis, Sobi, Novimmune, AB2 Bio; PQ: Consultant for AbbVie, Chugai-Roche, Lilly, Novartis, Pfizer, Sobi and speaker bureau for AbbVie, Chugai-Roche, Lilly, Novartis, Pfizer, Sobi; JA: Consultant for Sobi, Novartis, Roche, Pfizer, AbbVie, GSK; CL: Consultant for Sobi; RF: Previously employed by Sobi; VA: Previously employed by Sobi; MB: Previously employed by Sobi; PJ: Consultant for Sobi; CdM.: Consultant for Sobi, previously employed by Sobi.
Clinical Trial
NCT02069899 and NCT03311854
Funding Statement
NI-0501-05 and NI-0501-06 (ClinicalTrials.gov numbers, NCT02069899 and NCT03311854) were funded by Sobi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comitato Etico of the Ospedale Pediatrico Bambino Gesù and IRB or EC of all participatanting centers
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available on reasonable request. The data sharing policy of Sobi is available at the following site: https://www.sobi.com/en/policies. As noted on that site, requests for access to the study data can be submitted to medical.info{at}sobi.com.
